Sarka Pavlova
Overview
Explore the profile of Sarka Pavlova including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
363
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland J, Brieghel C, et al.
Hemasphere
. 2025 Jan;
9(1):e70065.
PMID: 39840379
In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41...
2.
Curylova L, Zambo I, Neradil J, Kyr M, Jurackova N, Pavlova S, et al.
Cell Oncol (Dordr)
. 2024 Dec;
47(6):2317-2334.
PMID: 39630408
Purpose: Pediatric sarcomas are bone and soft tissue tumors that often exhibit high metastatic potential and refractory stem-like phenotypes, resulting in poor outcomes. Aggressive sarcomas frequently harbor a disrupted p53...
3.
Stamatopoulos K, Pavlova S, Al-Sawaf O, Chatzikonstantinou T, Karamanidou C, Gaidano G, et al.
Hemasphere
. 2024 Jul;
8(7):e113.
PMID: 39035106
Patients with chronic lymphocytic leukemia (CLL) exhibit diverse clinical outcomes. An expanding array of genetic tests is now employed to facilitate the identification of patients with high-risk disease and inform...
4.
Kurucova T, Reblova K, Janovska P, Porc J, Navrkalova V, Pavlova S, et al.
Mol Oncol
. 2024 May;
18(10):2541-2553.
PMID: 38770541
Early identification of resistant cancer cells is currently a major challenge, as their expansion leads to refractoriness. To capture the dynamics of these cells, we made a comprehensive analysis of...
5.
Malcikova J, Pavlova S, Baliakas P, Chatzikonstantinou T, Tausch E, Catherwood M, et al.
Leukemia
. 2024 May;
38(7):1455-1468.
PMID: 38755420
In chronic lymphocytic leukemia (CLL), analysis of TP53 aberrations (deletion and/or mutation) is a crucial part of treatment decision-making algorithms. Technological and treatment advances have resulted in the need for...
6.
Navrkalova V, Plevova K, Radova L, Porc J, Pal K, Malcikova J, et al.
Br J Haematol
. 2023 Dec;
204(1):240-249.
PMID: 38062779
Large-scale next-generation sequencing (NGS) studies revealed extensive genetic heterogeneity, driving a highly variable clinical course of chronic lymphocytic leukaemia (CLL). The evolution of subclonal populations contributes to diverse therapy responses...
7.
Mancikova V, Pesova M, Pavlova S, Helma R, Zavacka K, Hejret V, et al.
Mol Oncol
. 2022 Nov;
17(1):82-97.
PMID: 36334078
TP53 gene abnormalities represent the most important biomarker in chronic lymphocytic leukemia (CLL). Altered protein modifications could also influence p53 function, even in the wild-type protein. We assessed the impact...
8.
Poppova L, Pavlova S, Gonzalez B, Kotaskova J, Plevova K, Dumbovic G, et al.
Epigenetics
. 2022 Mar;
17(12):1628-1635.
PMID: 35333703
Genome methylation profiles define naïve-like (n-CLL), memory-like (m-CLL), and intermediate (i-CLL) subsets of chronic lymphocytic leukaemia (CLL). The profiles can be easily determined by the analysis of the five-CpG signature....
9.
Dave Z, Vondalova Blanarova O, cada S, Janovska P, Zezula N, Behal M, et al.
Front Cell Dev Biol
. 2022 Mar;
10:838871.
PMID: 35295854
Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) are malignancies characterized by the dependence on B-cell receptor (BCR) signaling and by the high expression of ROR1, the cell surface...
10.
Urazbakhtin S, Smirnova A, Volakhava A, Zerkalenkova E, Salyutina M, Doubek M, et al.
Int J Mol Sci
. 2022 Feb;
23(3).
PMID: 35163677
Retroelements (RE) have been proposed as important players in cancerogenesis. Different cancer types are characterized by a different level of tumor-specific RE insertions. In previous studies, small cohorts of hematological...